Spark tAN device raises platelet activity in ear-nerve stimulation study
A 30-person first-in-human study found Spark Biomedical's non-invasive ear stimulation increased platelet function without triggering clotting risk, a hemostasis mechanism with no direct precedent in this class.
Executive Summary
- A first-in-human study of Spark Biomedical's ear-worn nerve stimulation platform found it increased platelet function in healthy volunteers without triggering unwanted clotting or safety events.
- The trial measured hemostasis and inflammation biomarkers rather than a clinical bleeding outcome, so the result is a mechanism signal that supports further study rather than a treatment effect in patients.
- No other program in the competitive field shares this combination of target, mechanism, and indication, leaving the approach without a direct precedent to benchmark against.
- The signal builds the case for testing the device in populations with actual bleeding risk, where the platelet-function finding would need to translate into a measurable clinical benefit.
The publication
Spark Biomedical and Northwell Health's Feinstein Institutes for Medical Research published a first-in-human study in Bioelectronic Medicine on July 13, 2026, reporting that Spark's tAN platform and transcutaneous auricular vagus nerve stimulation (taVNS) increased platelet function in healthy human subjects. The study reported no systemic coagulation effects, no hypercoagulability, and no adverse events. "For the first time, we have shown that Spark's core tAN technology can modulate neural circuits to enhance platelet readiness in humans," said Navid Khodaparast, PhD, Spark's chief science officer, in the announcement. SparkSpark Biomedical and Feinstein Institutes Publish First-in-Human Study Demonstrating Non-Invasive tAN® Technology Enhances Platelet FunctionJul 13, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
How it was done
The study is registered as NCT05977946, an interventional trial in adults enrolling 30 healthy volunteers under a randomized, two-arm design that used sham neurostimulation as the comparator. It measured six primary endpoints built on hemostasis biomarkers, including tissue anti-thrombin complex in fingerstick blood, D-dimer, viscoelasticity, and standard coagulation tests (prothrombin time and partial thromboplastin time) in circulating blood, plus inflammatory markers (TNF, IL-1B, IL-6) in blood stimulated ex vivo with lipopolysaccharide. The trial excluded participants with any bleeding, clotting, or coagulation history, and delivered stimulation through the ear via a transcutaneous route. NCT05977946Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human SubjectsNCT05977946
The result
Both stimulation modes, tAN and taVNS, increased platelet function without pushing blood toward a hypercoagulable state, according to the published findings. The registered primary endpoints were biomarker measures of hemostasis and inflammation rather than a clinical bleeding outcome, so the study establishes a proof-of-mechanism signal in healthy subjects rather than a therapeutic effect in a bleeding population. Jared Huston, MD, the Feinstein Institutes professor who led the study, said the wearable format "could one day be used in trauma settings, operating rooms, and for patients with bleeding disorders". Spark+1Spark Biomedical and Feinstein Institutes Publish First-in-Human Study Demonstrating Non-Invasive tAN® Technology Enhances Platelet FunctionJul 13, 2026Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human SubjectsNCT05977946
The field
No trial in the competitive landscape shares this target, mechanism, and indication combination: the nearest neighbors identified are other vagus- or trigeminal-nerve stimulation programs tested in different indications, such as post-traumatic stress disorder and cluster headache, and other healthy-volunteer studies of unrelated drug classes. That places the tAN hemostasis application in mechanistic isolation within the current field, with its nearest precedent limited to the modality (non-invasive nerve stimulation) rather than the specific hemostasis application.
Trial history
The underlying registry record shows the trial's primary completion date shifted eight times between 2023 and 2024, moving from February 2024 to an eventual August 2024 completion, with enrollment adjusted from 30 to 25 in November 2024 before the trial closed as Completed in December 2024. Those changes reflect a small, single-site healthy-volunteer study working through routine schedule adjustments before its 2026 publication, not a signal about the disclosed platelet-function result itself. NCT05977946Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human SubjectsNCT05977946
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.